Dr. Reddy's Laboratories Limited
Trial Pipeline
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
NCT03421197
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
NCT03116698
Pilot Study of Two Different Strengths of DFN-11 Injection for Rapidly Escalating Migraine
NCT02571049
A Study to Evaluate the Therapeutic Equivalence of Generic Permethrin Cream 5% to Elimite® in the Treatment of Scabies
NCT02572986
A Pediatric Safety and Pharmacokinetics Study of Ha44 Gel Administered Topically for Treatment of Head Lice Infestation
NCT02010333
An Efficacy and Safety Study of Ha44 Gel Administered Topically for the Treatment of Head Lice Infestation
NCT01336647
Bioavailability Study of Desloratadine 5 mg Tablet of Dr. Reddy's Under Fed Conditions
NCT01314352
Bioavailability Study of Ciprofloxacin 1000 mg ER Tablets of Dr. Reddy's Under Fasting Conditions
NCT01372345
Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions
NCT01161979
Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
NCT01161966
Bioequivalence Study of Ziprasidone HCL Capsules, 20 mg of Dr. Reddy's Under Fed Conditions
NCT01581879
Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.
NCT01131897
Bioequivalence Study for Lamotrigine Tablets 200 mg Under Fed Condition
NCT01513681
Bioequivalence Study of Isotretinoin Capsules 40 mg Under Fed Condition
NCT01888328
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Dr. Reddy's Laboratories Limited Shows
According to the ClinicalTrials.gov registry, Dr. Reddy's Laboratories Limited is linked to 14 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting — about 0% of the sponsor's indexed portfolio — and 14 are already marked complete, representing roughly 100% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Dr. Reddy's Laboratories Limited reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 13 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Dr. Reddy's Laboratories Limited is Healthy with 6 linked trials, and 8 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.